Basit öğe kaydını göster

dc.contributor.authorAgar, E.
dc.date.accessioned2020-06-21T13:41:26Z
dc.date.available2020-06-21T13:41:26Z
dc.date.issued2015
dc.identifier.issn0001-6314
dc.identifier.issn1600-0404
dc.identifier.urihttps://doi.org/10.1111/ane.12411
dc.identifier.urihttps://hdl.handle.net/20.500.12712/13950
dc.descriptionWOS: 000362751600001en_US
dc.descriptionPubMed: 25880465en_US
dc.description.abstractCannabinoids exert a neuroprotective influence on some neurological diseases, including Alzheimer's, Parkinson's, Huntington's, multiple sclerosis and epilepsy. Synthetic cannabinoid receptor agonists/antagonists or compounds can provide symptom relief or control the progression of neurological diseases. However, the molecular mechanism and the effectiveness of these agents in controlling the progression of most of these diseases remain unclear. Cannabinoids may exert effects via a number of mechanisms and interactions with neurotransmitters, neurotropic factors and neuropeptides. Leptin is a peptide hormone involved in the regulation of food intake and energy balance via its actions on specific hypothalamic nuclei. Leptin receptors are widely expressed throughout the brain, especially in the hippocampus, basal ganglia, cortex and cerebellum. Leptin has also shown neuroprotective properties in a number of neurological disorders, such as Parkinson's and Alzheimer's. Therefore, cannabinoid and leptin hold therapeutic potential for neurological diseases. Further elucidation of the molecular mechanisms underlying the effects on these agents may lead to the development of new therapeutic strategies for the treatment of neurological disorders.en_US
dc.language.isoengen_US
dc.publisherWileyen_US
dc.relation.isversionof10.1111/ane.12411en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectcannabinoid systemen_US
dc.subjectendocannabinoiden_US
dc.subjectCB1en_US
dc.subjectCB2en_US
dc.subjectleptinen_US
dc.subjectneurological diseasesen_US
dc.subjectbrainen_US
dc.titleThe role of cannabinoids and leptin in neurological diseasesen_US
dc.typereviewen_US
dc.contributor.departmentOMÜen_US
dc.identifier.volume132en_US
dc.identifier.issue6en_US
dc.identifier.startpage371en_US
dc.identifier.endpage380en_US
dc.relation.journalActa Neurologica Scandinavicaen_US
dc.relation.publicationcategoryDiğeren_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster